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Background. Introduced in 1942, sulfasalazine (a conjugate of 5-aminosalicylic acid (5-ASA) and sulfapyridine) is the most
prescribed medication used to treat ‘‘inflammatory’’ bowel disease (IBD.) Although controversial, there are increasingly
compelling data that Mycobacterium avium subspecies paratuberculosis (MAP) may be an etiological agent in some or all of
IBD. We have shown that two other agents used in the therapy of IBD (methotrexate and 6-MP) profoundly inhibit MAP
growth. We concluded that their most plausible mechanism of action is as antiMAP antibiotics. We herein hypothesize that the
mechanism of action of 5-ASA and/or sulfapyridine may also simply be to inhibit MAP growth. Methodology. The effect on
MAP growth kinetics by sulfasalazine and its components were evaluated in bacterial culture of two strains each of MAP and M.
avium, using a radiometric (
14CO2 BACTECH) detection system that quantifies mycobacterial growth as arbitrary ‘‘growth index
units’’ (GI). Efficacy data are presented as ‘‘percent decrease in cumulative GI’’ (%2DcGI). Principal Findings. There are
disparate responses to 5-ASA and sulfapyridine in the two subspecies. Against MAP, 5-ASA is inhibitory in a dose-dependent
manner (MAP ATCC 19698 46%2DcGI at 64 mg/ml), whereas sulfapyridine has virtually no effect. In contrast, against M. avium
ATCC 25291, 5-ASA has no effect, whereas sulfapyridine (88%2DcGI at 4 mg/ml) is as effective as methotrexate, our positive
control (88%2DcGI at 4 mg/ml). Conclusions. 5-ASA inhibits MAP growth in culture. We posit that, unknowingly, the medical
profession has been treating MAP infections since sulfasalazine’s introduction in 1942. These observations may explain, in part,
why MAP has not previously been identified as a human pathogen. We conclude that henceforth in clinical trials evaluating
antiMAP agents in IBD, if considered ethical, the use of 5-ASA (as well as methotrexate and 6-MP) should be excluded from
control groups.
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INTRODUCTION
In 1942 sulfasalazine (‘‘Salazopyrin’’) was introduced into clinical
practice for ulcerative colitis. [1] Sulfasalazine has become, because
of empirically observed clinical efficacy, ‘‘the most common
medicine used to treat ‘‘Inflammatory’’ Bowel Disease (IBD) [2]
with greatest efficacy in ulcerative colitis. [3–5]
Sulfasalazine is a conjugate of sulfapyridine and 5- aminosa-
licylic acid (5-ASA.) It is cleaved into its two component molecules
following ingestion. [2] The sulfapyridine moiety [(2-(p amino-
benzenesulphonamido) pyridine] is an acknowledged antibiotic.
[6,7] However, prevailing medical dogma concludes that ‘‘it is
unlikely that (sulfasalazine’s) antibacterial activity accounts for its
clinical efficacy.’’ [2] In 1977, a two-week study on ulcerative
proctitis, compared 5-ASA to sulfapyridine. Because of a decrease
in inflammation in the 5-ASA group, the authors concluded, that
in the therapy of ulcerative colitis the active moiety of sulfasalazine
was 5-ASA. [8] As a consequence therapy with 5-ASA is called
‘‘anti-inflammatory’’ although ‘‘the mechanism of action of 5-ASA
in IBD is uncertain.’’ [2]
Although controversial, there are increasingly compelling data
that all [9,10] or some of IBD may be caused by a single infectious
agent Mycobacterium avium subspecies paratuberculosis (MAP.) [9–13]
(& See [14] for review.) We have shown that two agents, metho-
trexate and 6-mercaptopurine (6-MP) [10], presumed to have
‘‘immunomodulatory’’ actions in IBD, [15,16] are potent
antiMAP antibiotics. We suggested that the decreases in pro-
inflammatory cytokines in IBD ‘‘immunomodulatory’’ therapy
might simply reflect a normal, secondary, physiological response,
as the instigating MAP infection was effectively treated. We
concluded that henceforth methotrexate and 6-MP should be
excluded from the placebo group when evaluating antiMAP
therapies in IBD. [10]
In this study we test the hypothesis that the ‘‘anti-inflammatory’’
action of 5-ASA and/or sulfapyridine could simply be due to one
or both of sulfasalazine’s components acting as an antiMAP
antibiotic(s.) If correct the ‘‘anti-inflammatory’’ effect would
simply represent a normal, secondary, physiological response as
the causative MAP infection was controlled by antiMAP antibiotic
action. Accordingly, in bacterial culture, we have evaluated the
effect of sulfasalazine and individually and in combination its
cleavage products 5-ASA and sulfapyridine, on M. avium including
its subspecies MAP.
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This study was approved by the Research & Development
Committee at the VAMC Bronx NY (0720-06-038) and was
conducted under the Institutional Radioactive Materials Permit
(#31-00636-07).
Bacterial Culture:
In this study (as previously [10]) we use four well-characterized
strains of mycobacteria. Two are MAP, a bovine isolate, ATCC
19698 (ATCC Rockville MD) and ‘‘Dominic’’ a human isolate
from an individual with Crohn’s disease (originally isolated by R.
Chiodini [17].) The M. avium subspecies avium strains (hereinafter
called M. avium) were ATCC 25291 (veterinary source) and M.
avium 101. [18] Because it renders clinically resistant strains of
MAP inappropriately susceptible to antimicrobials in cell culture,
[19] we did not use the detergent Tween 80 (recommended to
prevent mycobacterial clumping) in culture. Prior to inoculation
cultures were processed as described. [10] [20]
Our negative control was intact sulfasalazine (a conjugate of
sulfapyridine & 5-ASA) and the positive control was methotrexate.
[10] Sulfapyridine and 5-ASA were evaluated individually and in
combination (All from Sigma St Louis MO.) Aliquots of chemicals
being evaluated were prediluted, stored at 280uCi n5 0 m M
NaOH, thawed, used once and discarded. Volumes of NaOH
were adjusted so that final concentration in each Bactec vial was
always 3.2 mM NaOH. Agents were tested in serial dilutions from
a minimum of 0.05 mg/ml to a maximum of 64 mg/ml (see
individual Figures). When the individual molecules 5-ASA and
sulfapyridine were studied in combination, the same weight for
each was used as when tested individually (see appropriate Table.)
Data for the Bactec H System (Becton-Dickinson Franklin Lakes
NJ) are presented as cumulative growth index (cGI) units6SD
(when necessary, see individual figures). cGI data for each
experiment is presented until the day prior to any GI reading
exceeding the assay limit of ‘‘999.’’ The effect (or lack thereof) of
each agent is presented as the percent decrease in cGI units
(%2DcGI), The calculation of %2DcGI is performed in two
stages (using Excel) according to the formula:
Step one~ A{B ðÞ =A ½  ~C Step two~{C|%~
Final result of % {DcGI
Where A=the cGI of the control inoculum for the given diluent
(usually in these experiments NaOH); B=the cGI for the
particular chemical at a particular dose being tested, incubated
for the same number of days as A. C=the product of [(A2B)/A].
Raw data were archived onto Excel, collated and the cumulative
results transferred to Prism (Graphpad, San Diego CA) for final
graphing.
RESULTS
Data for the effect of test agents on bacterial growth are presented
in two ways. Either as results for an individual mycobacterial strain
(Figures 1 & 2) or as a comparison of the effect of each agent tested
on all four mycobacterial strains in Tabular form, where inhibition
isexpressedas%2DcGI,andenhancementas%+DcGI(Tables1–
5.) Tables 1 & 2 are the experimental controls; Table 1=the
positive control methotrexate & Table 2=the negative control
sulfasalazine. Tables 3–5 have the agents tested, 5-ASA (Table 3),
sulfapyridine (Table 4) and the combination of 5-ASA+sulfapyr-
idine (Table 5.)
The positive control is methotrexate, previously shown to be
almost as effective as the acknowledged antiMAP antibiotic clari-
thromycin. [10] There is$80%2DcGI at 4 mg/ml for all four
species (Figures 1 & 2 and Table 1). In the MAP Dominic study
(Figure 2), the positive control was clarithromycin, which because
it was diluted in methanol was off scale, but showed maximal
inhibition by 1 mg/ml (data not presented).
The negative control is the intact progenitor molecule sulfas-
alazine. [1] Sulfasalazine is manufactured by combining 5-ASA
with sulfapyridine. Surprisingly, rather than having no effect or
inhibiting mycobacterial growth we found that intact sulfasalazine
actually enhances growth at high doses (Figures 1 and 2 & Table 2).
By 64 mg/ml, sulfasalazine increases both MAP ATCC 19698 and
Dominic by 27%+DcGI, (Figures 1 & 2 and Table 2) and of M.
avium ATCC 25291 by 160%+DcGI (Figure 2 and Table 2.)
There are two different responses for MAP compared to M.
avium from the two cleavage products of intact sulfasalazine, 5-
ASA and sulfapyridine. Against MAP, 5-ASA has dose dependent
inhibition. At 64 mg/ml of 5-ASA, inhibition against MAP ATCC
19608 is 46%-DcGI (Figures 1 & 2 and Table 3), and against
Dominic inhibition is 17%-DcGI (Figure 2 and Table 3). In
contrast, sulfapyridine alone has no inhibition against either MAP
strain (Figures 1 and 2 and Table 4.)
In contrast to MAP, both M. avium strains are very susceptible to
sulfapyridine. Inhibition is 88%-DcGI at 4 mg/ml for ATCC
25291 and 92%-DcGI at 4 mg/ml for M. avium 101 (Figure 2 and
Table 4.) M. avium is not inhibited by 5-ASA, (Figure 2 and
Table 4.)
Finally, the two components 5-ASA and sulfapyridine were
studied in combination. For experimental comparability, equal
doses of each agent were used (See Left Hand column in Table 5.)
In two of the three MAP studies there is subtle evidence of synergy
when the 5-ASA/sulfapyridine combinations are used (Figure 2
and Table 5.) This possible synergy is not seen in the MAP data
presented in Figure 1. Different numbers of CFU’s were inoculated
in the two MAP ATCC 19698 studies. In the experiment from
Figure 1 we inoculated 2.7610
4 CFU’s and the experiment lasted
11 days and in Figure 2, 6610
4 CFU’s were inoculated and the
experiment lasted 10 days. There is no evidence of any 5-ASA/
sulfapyridine synergy with either M. avium strain (Figure 2 and
Tables 3–5.)
DISCUSSION
Although its precise mechanism of action has never been
established, the utility of sulfasalazine (or 5-ASA alone) in the
therapy of IBD, is uncontested since Svartz’s seminal publication
in 1942. [1] Sulfasalazine has been used because of empirical
efficacy and prevailing medical dogma accepts that it acts in a non-
specific ‘‘anti-inflammatory’’ manner. In the event that IBD is
eventually accepted as being due to a MAP infection, our data are
compatible with our hypothesis that the efficacy of 5-ASA is due to
impairment of MAP growth.
Results with our positive control methotrexate, replicate our
previous findings against all the M. avium strains studied. [10] In
this study, our negative control is the intact progenitor molecule
sulfasalazine that comprises sulfapyridine linked to 5-ASA. We
show it has virtually no inhibitory action, and at high doses intact
sulfasalazine actually enhances growth in all the strains studied.
The mechanism(s) whereby mycobacteria are able to utilize
uncleaved sulfasalazine remain to be elucidated.
We show completely different responses to 5-ASA and sulfapy-
ridine in the two M. avium subspecies studied. Against MAP, 5-
ASA is inhibitory in a dose dependent manner, whereas sulfapyri-
dine alone has minimal effect. Our data therefore offer a rational
5-ASA & paratuberculosis
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4 CFU/vial of MAP ATCC 19698 was inoculated into each Bactec vial. Each drug dilution was studied in
duplicate. Error bars are SD. The positive control is methotrexate, with maximal inhibition by 8 mg/ml. Neither the negative control sulfasalazine, nor
sulfapyridine, have any inhibition. Both and 5-ASA alone and in combination with sulfapyridine have dose dependent inhibition.
doi:10.1371/journal.pone.0000516.g001
Figure 2. A composite graph of the two MAP and two M. avium bacterial strains studied. Each dose was studied in singlicate. For MAP ATCC 19698,
6610
4 CFU’swereinoculated/vial.Sulfasalazineisthe negativecontrolforbothMAP andM.aviumstrains.Inallstrains thereis dosedependentincreasein
cGI. There is no inhibition by sulfapyridine alone with either MAP strain. 5-ASA has dose dependent inhibition on both MAP strains. Note the subtle
synergy up to 16 mg/ml for both MAP strains for the 5-ASA+sulfapyridine group compared to 5-ASA alone. The positive control in the Dominic study was
clarithromycin which, because it was diluted in methanol, is off scale. Accordingly, the clarithromycin data are not presented.
doi:10.1371/journal.pone.0000516.g002
5-ASA & paratuberculosis
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[8], showing that 5-ASA is more active than sulfapyridine in the
therapy of ulcerative proctitis. As a consequence, we suggest that
the ‘‘anti-inflammatory’’ effect of 5-ASA may simply represent
a normal, physiological, secondary response as an instigating MAP
infection is treated.
In contrast, we observe that sulfapyridine is as effective as the
positive control methotrexate against M. avium subspecies avium,
whereas 5-ASA has no effect. We conclude that unlike its utility in
putative MAP infections, 5-ASA has no role to play in M. avium
subspecies avium infections.
As is conventional in studies such as these, we evaluated each
agent on an equal weight basis. The data show that against MAP,
5-ASA is not nearly as effective as methotrexate. Our data are
therefore consistent with many decades of empirical clinical
observation with 5-ASA and methotrexate. Neither 5-ASA nor
methotrexate has traditionally been administered as an ‘‘antibiot-
ic.’’ Their dosage has been determined by titration to clinical
efficacy and limited by side effects. For sulfasalazine, the
recommended dosage is #4 gm/day, as tolerated. [3] In contrast,
for methotrexate the usual ‘‘low dose’’ [10] that is used to treat
‘‘inflammatory’’ diseases such as IBD is 25 mg/week. [21] This
.1000 fold difference (28,000 mg/wk sulfasalazine compared to
25 mg/wk methotrexate) is compatible with our data both in this
manuscript and previously [10] showing that methotrexate is, on
a weight/weight basis, far more effective than 5-ASA at inhibiting
MAP growth.
In the clinical therapy of IBD, either sulfasalazine or one of its
components, 5-ASA is used. Sulfapyridine is not used alone. Our
culture inhibition data offer a rational explanation for these
Table 2. Negative Control: Intact Sulfasalazine
......................................................................
Sulfasalazine MAP M. avium
ATCC 19698 Dominic ATCC 25291 101
mg/ml Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig 2
0.5 22% 50%
1 13% 216% 10% 227% 21%
25 % 246%
4 14% 29% 4% 27% 23%
8 22% 218%
16 22% 10% 9% 36% 1%
32 20% 86%
64 27% 13% 27% 160% 15%
%2DcGI
doi:10.1371/journal.pone.0000516.t002
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Table 3. Test Agent: 5-ASA
......................................................................
5-ASA MAP M. avium
ATCC 19698 Dominic ATCC 25291 101
mg/ml Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2
0.5 2% 26%
1 28% 217% 21% 231% 28%
2 25% 80%
4 218% 228% 211% 29% 24%
8 226% 232%
16 233% 242% 216% 220% 21%
32 247% 23%
64 246% 244% 217% 55% 4%
%2DcGI
doi:10.1371/journal.pone.0000516.t003
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Table 4. Test Agent: Sulfapyridine
......................................................................
Sulfapyridine MAP M. avium
ATCC 19698 Dominic ATCC 25291 101
mg/ml Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2
0.5 12% 247%
11 8 % 210% 23% 25% 22%
21 4 % 260%
41 8 % 28% 1% 288% 28%
81 7 % 293%
16 21% 1% 0% 293% 288%
32 17% 293%
64 13% 1% 4% 293% 298%
%2DcGI
doi:10.1371/journal.pone.0000516.t004
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Table 1. Positive Control: Methotrexate
......................................................................
Methotrexate MAP M. avium
ATCC 19698 Dominic [10] ATCC 25291 101
mg/ml Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig 2
0.5 213% 244%
1 227% 228% 252% 52% 220%
2 272% 272%
4 283% 259% 289% 292% 282%
8 296% 293%
16 298% 297% 293% 292% 299%
32 298% 294%
64 298% 298% 293% 294% 298%
%2DcGI
doi:10.1371/journal.pone.0000516.t001
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Table 5. Test Agents: 5-ASA+Sulfapyridine
......................................................................
5-ASA+
Sulfapyridine MAP M. avium
ATCC 19698 Dominic ATCC 25291 101
mg/ml Fig. 1 Fig. 2 Fig. 2 Fig. 2 Fig. 2
0.5+0.5 22% 28%
1+11 6 % 227% 214% 251% 25%
2+2 22% 244%
4+4 212% 242% 220% 291% 217%
8+8 229% 293%
16+16 232% 249% 224% 292% 283%
32+32 234% 293%
64+64 220% 235% 216% 292% 298%
%2DcGI
doi:10.1371/journal.pone.0000516.t005
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subtle synergy when sulfapyridine is added to 5-ASA at higher
inoculation counts. These observations need to be replicated in
more MAP strains, different CFU inoculation counts and other
inhibition methods. [22] Additionally, to prevent the emergence of
resistant strains, single antibiotic therapy is not acceptable in the
therapy of other mycobacterial diseases such as leprosy. [23] We
conclude that, unless there is a sulfapyridine allergy, it may be
preferable to treat with the combination medication sulfasalazine
in preference to 5-ASA alone.
Previously we documented the antiMAP action of the
‘‘immune-modulators’’ methotrexate and 6-MP. We now show
that the ‘‘anti-inflammatory’’ 5-ASA likewise has antiMAP action.
These medications are bedrock ‘‘immuno-modulatory’’ and ‘‘anti-
inflammatory’’ therapies in IBD and other ‘‘inflammatory’’ and
‘‘auto-immune’’ diseases. Our data raise the reasonable concern
that an infectious cause of IBD has been overlooked, simply
because the infectious agent has unknowingly been treated since
1942. It is therefore possible that the ‘‘I’’ in ‘‘I’’BD could stand for
‘‘Infectious’’ and that the causative organism may be MAP.
We conclude that, since the placebo groups were receiving
active antiMAP agents, prior studies that evaluated antiMAP
agents need to be revaluated. Clinicians who continue to opine
that MAP is not zoonotic will now need to substantiate their
position. To do so they will need to conduct trials that exclude
agents that we show have antiMAP activity from the placebo
group. However, the ethical implications of excluding these agents
[24] (see particularly Note of Clarification on Paragraph 29 added
by the World Medical Association General Assembly, Washington
2002) will need to be fully addressed when they design their
protocols.
Conclusions and Recommendations
We show that the ‘‘anti-inflammatory’’ agent 5-ASA, interferes
with the growth of MAP, an organism that may be the etiological
factor for some, or all of IBD. Some of the implications of these
observations are discussed.
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